Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Panoptic AG Solutions LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves 2 distinct examiners and 2 distinct art units. The use of these 2 distinct examiners for the pending actions suggests a lack of examiner continuity, requiring the applicant to navigate different individual preferences for each case.
ISNOR, ALEXANDRA NICOLE is the busiest examiner for the company, holding 1 pending office action. The presence of 2 distinct art units for only 2 pending actions reflects a fragmented examination landscape for the current portfolio. This distribution implies that the subject matter of the pending office actions is diverse enough to fall under different supervisory groups. Practitioners should be prepared for the 2 distinct examiners to apply different standards of evidence or prior art interpretations during the prosecution of these biotechnology applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISNOR, ALEXANDRA NICOLE | 1 | 26.1% | +26.2% |
| LANGEL, WAYNE A | 1 | 78.3% | +23.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17956221 | UREA CYCLE AUGMENTING COMPOSITION AND METHODS OF USE | LANGEL, WAYNE A | 69d |
| 18074271 | PLANT METABOLISM PROMOTING COMPOSITIONS AND METHODS OF USE | ISNOR, ALEXANDRA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17956221 | UREA CYCLE AUGMENTING COMPOSITION AND METHODS OF USE | LANGEL, WAYNE A | 69d |
| 18074271 | PLANT METABOLISM PROMOTING COMPOSITIONS AND METHODS OF USE | ISNOR, ALEXANDRA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1736 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18074271 | PLANT METABOLISM PROMOTING COMPOSITIONS AND METHODS OF USE | ISNOR, ALEXANDRA NICOLE | 1611 | §103DP | Non-Final OA | — | Pending | Dec 02, 2022 |
| 17956221 | UREA CYCLE AUGMENTING COMPOSITION AND METHODS OF USE | LANGEL, WAYNE A | 1736 | §102§103 | Non-Final OA | 69d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPanoptic AG Solutions LLC has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Alexandra Nicole Isnor has the most, with 1 of Panoptic AG Solutions LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.